A Highly Sensitive Flow Cytometric Approach to Detect Rare Antigen-Specific T Cells: Development and Comparison to...

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Personalized vaccines targeting tumor-associated antigens are key in cancer immunotherapy.
• Assessing vaccine efficacy relies on quantifying antigen-specific T-cell responses.
• Existing methods like ELISpot and standard FCM struggle with low-frequency T-cell signals.

Purpose of the Study:

• To develop a more sensitive flow cytometry (FCM) method for detecting rare T-cell responses.
• To improve the monitoring of personalized cancer vaccine efficacy.

Main Methods:

• Developed an enhanced FCM panel incorporating early activation markers 4-1BB (CD137) and CD40L (CD154).
• Compared the new FCM panel against standard FCM and ELISpot for sensitivity in detecting T-cell responses.
• Measured frequencies of antigen-specific T cells, including IFNγ-producing cells.

Main Results:

• Standard FCM and ELISpot showed high background IFNγ secretion, often exceeding the antigen-specific signal.
• The enhanced FCM panel significantly reduced background noise, with frequencies decreasing by 19-fold for CD4 T cells and 13-fold for CD8 T cells.
• The new method enabled sensitive quantification of rare T-cell populations responding to tumor antigens.

Conclusions:

• The enhanced FCM methodology offers a highly sensitive approach for monitoring T-cell responses to tumor-associated antigens.
• This technique is crucial for evaluating the clinical relevance of low-frequency T-cell responses in cancer immunotherapy.
• The improved detection of T-cell activity supports the development and application of personalized cancer vaccines.